Silo Pharma (SILO) News Today → “Dollar Will Be Worth NOTHING” -Musk (From Crypto 101 Media) (Ad) Free SILO Stock Alerts $1.88 +0.07 (+3.87%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 8:45 AM | globenewswire.comSilo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in KetamineMay 13, 2024 | americanbankingnews.comAnalyzing Amer Sports (NYSE:AS) & Silo Pharma (NASDAQ:SILO)May 1, 2024 | msn.comMultiple sclerosis patients find hope in ‘liquid gold’April 30, 2024 | msn.com‘Liquid gold’ could bring new hope to multiple sclerosis patients, study suggests: ‘Profound benefit’April 25, 2024 | investing.comSilo Pharma reports promising SPC-15 study for PTSD therapyApril 25, 2024 | finance.yahoo.comSilo Pharma, Inc. (SILO) Stock Price, News, Quote & History - Yahoo FinanceApril 23, 2024 | finance.yahoo.comSilo Pharma Announces Positive Results for Intranasal PTSD TreatmentApril 23, 2024 | globenewswire.comSilo Pharma Announces Positive Results for Intranasal PTSD TreatmentApril 17, 2024 | msn.comPsyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & MoreApril 10, 2024 | finanznachrichten.deSilo Pharma, Inc.: Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer's Disease TherapeuticApril 10, 2024 | markets.businessinsider.comSilo Pharma Exercises Option To License AD Therapeutic SPC-14 From Columbia UniversityApril 10, 2024 | finance.yahoo.comSilo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease TherapeuticApril 10, 2024 | globenewswire.comSilo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer's Disease TherapeuticMarch 20, 2024 | finance.yahoo.comSilo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety TherapeuticMarch 18, 2024 | globenewswire.comSilo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic PainMarch 14, 2024 | finance.yahoo.comGlobal Psychedelic Drugs Market Size To Worth USD 8.7 Billion By 2033 | CAGR of 11.61%March 11, 2024 | msn.comElectoral bonds case: Supreme Court dismisses SBI’s appeal for extension of deadline, directs disclosure by March 12February 29, 2024 | morningstar.comSILO Pharma Inc SILOFebruary 28, 2024 | finanznachrichten.deSilo Pharma, Inc.: Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSDFebruary 28, 2024 | globenewswire.comSilo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSDFebruary 14, 2024 | finanznachrichten.deSilo Pharma, Inc.: Silo Pharma's SP-26 Ketamine Implant Demonstrates Successful Drug DeliveryFebruary 14, 2024 | finance.yahoo.comSilo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug DeliveryFebruary 14, 2024 | globenewswire.comSilo Pharma's SP-26 Ketamine Implant Demonstrates Successful Drug DeliveryFebruary 5, 2024 | nytimes.comExploring Ghana, With Contemporary Art as a GuideFebruary 1, 2024 | finance.yahoo.comSilo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and NeurologyJanuary 24, 2024 | marketwatch.comSilo Pharma Sees Positive Data From Study for Alzheimer's TreatmentJanuary 24, 2024 | finance.yahoo.comSilo Pharma Announces Positive Results in Alzheimer’s Disease StudyJanuary 4, 2024 | finance.yahoo.comSilo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSDDecember 28, 2023 | msn.comFibromyalgia Care Breakthrough: DEA Green Lights Biotech Partnership Exploring Ketamine Implant TherapyDecember 28, 2023 | finanznachrichten.deSilo Pharma, Inc.: Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for FibromyalgiaDecember 28, 2023 | marketwatch.comSilo Pharma Shares Fall 9% on Initial Approvals for Ketamine Implant for FibromyalgiaDecember 28, 2023 | finance.yahoo.comSilo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for FibromyalgiaNovember 21, 2023 | msn.comSilo Pharma Collaborates With Medspray Pharma For Intranasal Technology For Stress Disorder CandidateNovember 21, 2023 | msn.comSilo Pharma stock rises after inking exclusive license deal with Medspray PharmaNovember 21, 2023 | finance.yahoo.comSilo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSDNovember 5, 2023 | thestreet.comSILO Pharma IncOctober 16, 2023 | finance.yahoo.comSilo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid ArthritisOctober 11, 2023 | finanznachrichten.deSilo Pharma, Inc.: Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSDSeptember 23, 2023 | yahoo.comSilo Season 2 Release Date Rumors: When Is It Coming Out?September 20, 2023 | finance.yahoo.comSilo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDASeptember 12, 2023 | finance.yahoo.comSilo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSDSeptember 5, 2023 | markets.businessinsider.comPsyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & MoreAugust 28, 2023 | msn.comLaidlaw starts Silo at buy, cites valuation and CNS drug candidatesAugust 28, 2023 | msn.comLaidlaw & Co. Initiates Coverage of SILO Pharma (SILO) with Buy RecommendationAugust 8, 2023 | benzinga.comBreaking Ground In Prevention & Relief Of Anxiety & PTSD: Silo Pharma' Nasal Formulation For Ketamine-Based TreatmentAugust 8, 2023 | finance.yahoo.comSilo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related DisordersJuly 18, 2023 | theglobeandmail.comSilo Pharma (NASDAQ: SILO) Reports Positive Results from SPU- 21 Arthritis StudyJune 23, 2023 | benzinga.comSilo Pharma Says Co Working On Time-Release, Dosage Ketamine Implant And TopicalJune 23, 2023 | finance.yahoo.comPsychedelics Company Silo Pharma Working On Time-Release And Dosage Ketamine Implant And Topical, Hoping To Deliver Steady Pain Relief For Four Million Fibromyalgia SufferersJune 22, 2023 | marketwatch.comSilo Pharma's SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent Get Silo Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for SILO and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden FINISHED On June 13th? (Ad)Thanks to Biden’s disgraceful leadership we now have sky-high inflation… unchecked immigration… rampant crime… and a “woke mob” hell bent on destroying the America you and I know and love. Biden’s days are numbered. Click here now to see his shocking evidence. SILO Media Mentions By Week SILO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SILO News Sentiment▼-0.020.55▲Average Medical News Sentiment SILO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SILO Articles This Week▼51▲SILO Articles Average Week Get Silo Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for SILO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: NexImmune News Today Seelos Therapeutics News Today ZyVersa Therapeutics News Today Synaptogenix News Today Shineco News Today Kazia Therapeutics News Today Genprex News Today Petros Pharmaceuticals News Today Bright Minds Biosciences News Today China Pharma News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SILO) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the MarketsHow Biden has already won 2024Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityGold Set to EXPLODE!Gold Safe ExchangeBiden FINISHED On June 13th?Paradigm PressThe 1,000X Crypto PlaybookTrue Market InsidersWhy Is Gold On a MASSIVE rally? Huge AlertsShocking $16T Elon Musk Crypto LeakCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silo Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
